Results 41 to 50 of about 2,248,512 (380)
Molecular Oncology, EarlyView.Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker +14 more
wiley +1 more source
Health care and lost productivity costs of overweight and obesity in New Zealand
Australian and New Zealand Journal of Public Health, 2012 Objective: To estimate the costs of health care and lost productivity attributable to overweight and obesity in New Zealand (NZ) in 2006. Methods: A prevalence‐based approach to costing was used in which costs were calculated for all cases of disease in ...
Anita Lal +4 more
doaj +1 more source
Deep learning for prediction of population health costs [PDF]
arXiv, 2020 Accurate prediction of healthcare costs is important for optimally managing health costs. However, methods leveraging the medical richness from data such as health insurance claims or electronic health records are missing. Here, we developed a deep neural network to predict future cost from health insurance claims records.
arxiv
Estimating medical costs from a transition model [PDF]
IMS Collections 2008, Vol. 1, 350-363, 2008 Nonparametric estimators of the mean total cost have been proposed in a variety of settings. In clinical trials it is generally impractical to follow up patients until all have responded, and therefore censoring of patient outcomes and total cost will occur in practice.
arxiv +1 more source
High and Rising Health Care Costs: Demystifying U.S. Health Care Spending [PDF]
, 2008 Reviews the data used to measure U.S. healthcare costs and examines long- and short-term trends, whether costs are too high, how they compare to those of other developed nations, and what factors are driving the growth.
Paul B. Ginsburg
core
Molecular Oncology, EarlyView.In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen +13 more
wiley +1 more source
Long-term medical and productivity costs of severe trauma: Results from a prospective cohort study.
PLoS ONE, 2021 BackgroundThrough improvements in trauma care there has been a decline in injury mortality, as more people survive severe trauma. Patients who survive severe trauma are at risk of long-term disabilities which may place a high economic burden on society ...
Marjolein van der Vlegel +5 more
doaj +1 more source
Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients
Molecular Oncology, EarlyView.Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha +6 more
wiley +1 more source
A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer
Molecular Oncology, EarlyView.Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini +11 more
wiley +1 more source
Maternity Care and Consumer-Driven Health Plans [PDF]
, 2007 Compares out-of-pocket costs of maternity care under consumer-driven health plans (CDHP) to a traditional health insurance plan. Explores related factors including prenatal care coverage and unpredictability of costs for delivery and hospital ...
Alina Salganicoff +3 more
core